Pharma Focus Asia

Thermo Fisher Constructs New cGMP Plasmid DNA Manufacturing Facility in California

Introduction:
Thermo Fisherplans to construct a new manufacturing facility for the production of clinical and commercial capabilities. The facility will be located in Carlsbad, California. The expansion of this facility enhances the commercialisation of plasmid-based medicines and vaccines.

Features:
The facility is constructed with an area covering 67,000-square-foot. The new start-of-art-facility is designed with advanced technologieswhich usesingle-use equipment with up to 1,000L scale, allowing operational efficiencies and operator training with digital connectivity and data visibility.

It also expands commercial and clinical capabilities for plasmid DNA which can be used as a raw material for manufacturing cell and gene therapies for cancer treatments as well as mRNA vaccines. Moreover, the facility not only deals with supply bottleneck for customers, but also helps indelivering robust end-to-end cell and gene therapy capabilities.

It is expected that the new manufacturing facility will complete its construction in the first half of 2021. It is estimated that the new site will create approximately 150 jobs.

Specifications:

NameThermo Fisher Scientific
TypeExpansion
YearQ1 2021

 

magazine-slider-imageMFA + MMA 2024CPHI Chine || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopNitrosamine Advance Workshop 2024CPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024Rehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024LogiPharma Asia 2024